Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archinte.130.6.943 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vaccination practices and knowledge among adults with hemoglobinopathies in Greece: a nationwide survey.
Ther Adv Vaccines Immunother
September 2024
Department of Pediatrics, Penteli's Children's Hospital, Athens, Greece.
Article Synopsis
- Hemoglobinopathies like sickle cell disease and thalassemia lead to health complications, increasing infection risks, making vaccinations essential for patient care and quality of life.
- A nationwide survey in Greece assessed vaccination coverage and attitudes toward vaccination among patients with hemoglobinopathies using a 37-item anonymous questionnaire.
- Results showed that while childhood vaccination rates were generally in line with national standards, adult vaccination coverage was low for several key vaccines, particularly among individuals over 50 years, who also had more misconceptions about vaccinations.
Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials.
Kidney Med
August 2024
Division of Pediatric Nephrology, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA.
Rationale & Objective: Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) caused by complement dysregulation. Ravulizumab is a C5i approved for the treatment of aHUS. This analysis assessed long-term outcomes of ravulizumab in adults and pediatric patients with aHUS.
View Article and Find Full Text PDFSafety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study.
Adv Ther
May 2024
Center for Integrated Oncology, Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany.
Article Synopsis
- - PNH is a serious condition that leads to blood issues, and pegcetacoplan is a new therapy that targets a specific part of the immune system to help treat it; clinical trials show it works well and is safe for patients.
- - In a follow-up study (307 OLE), 137 patients who received pegcetacoplan showed significant improvements in hemoglobin levels and reduced fatigue, with most not needing blood transfusions over the study period.
- - Results indicated 40.2% of patients achieved hemoglobin levels above 12 g/dL, and while some experienced hemolysis, there were no major complications like blood clots or infections reported.
Identifying Barriers to HPV Vaccination for Patients With Sickle Cell Disease and Childhood Cancer Survivors.
J Pediatr Hematol Oncol
November 2023
Department of Pediatrics, Division of Adolescent Medicine, Indiana University School of Medicine.
Human papillomavirus (HPV) vaccination prevents the development of HPV-associated malignancies. Adolescent and young adult survivors of childhood cancers and patients with sickle cell disease (SCD) are vulnerable patient populations who would significantly benefit from HPV vaccination. In this multimethod study, a retrospective chart review found a notable difference between the rate of HPV vaccinations and other age-appropriate vaccinations in 177 childhood cancer survivors and in 70 patients with SCD.
View Article and Find Full Text PDFA Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM).
Clin Infect Dis
October 2023
Merck & Co., Inc., Rahway, New Jersey, USA.
Background: Individuals who receive allogeneic hematopoietic cell transplant (allo-HCT) are immunocompromised and at high risk of pneumococcal infections, especially in the months following transplant. This study evaluated the safety and immunogenicity of V114 (VAXNEUVANCE; Merck, Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!